Copanlisib Could Be a Viable Therapeutic Option for Select PIK3CA-Mutated Cancers
Findings from the NCI-MATCH tumour-agnostic platform subprotocol study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Implementation of Molecular Tumour Board Portal Developed Under the Umbrella of Cancer Core Europe
An academic clinical decision support system to better address the challenges of delivering biomarker-driven oncology
EMA Recommends Extension of Therapeutic Indications for Atezolizumab
New indication concerns the adjuvant treatment of patients with early-stage non-small cell lung cancer
HBV Infection Associated with Increased Risk of Primary Extrahepatic Malignancies
Long-term nucleos(t)ide analogue treatment associated with lower risk of extrahepatic malignancy development among patients with chronic hepatitis B
Screen-Detected Colorectal Cancers Have a More Favourable Stage Distribution than Colorectal Cancers Detected Otherwise
Findings from a population-based study in 9 European countries
EMA Starts Review of Rucaparib
The review follows interim results from the ongoing ARIEL4 study indicating that overall survival was shorter in patients treated with rucaparib than in those who received chemotherapy
Incidence of Colorectal, Breast, Kidney, Pancreatic, and Uterine Cancers is Increasing in Young Adults
Findings from analysis of incidence trends for 12 cancer types
EMA Recommends Granting a Conditional Marketing Authorisation for Mosunetuzumab
It is intended for the treatment of adult patients with relapsed or refractory follicular lymphoma
Long-Term Responders with No Evidence of Disease Have Better Survival to First-Line HER2 Targeted Therapy for MBC
Patients with metastatic breast cancer and long-term response with no evidence of disease have better survival compared to those with residual disease
EMA Recommends Granting a Marketing Authorisation for Capmatinib
It is intended for treatment of patients with advanced NSCLC harbouring alterations leading to METex14 skipping
Antitumour Activity and Favourable Safety Demonstrated After Treatment with Nivolumab and Ipilimumab Combined with SBRT for Refractory Metastatic Pancreatic Cancer
Findings from the CheckPAC study
Remote Monitoring of Patients Treated with Oral Anticancer Drugs Improves Patient Care Experience and Optimises Healthcare Resources
Findings from a randomised phase III CAPRI study